Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Chronic heart failure; Renal impairment
- Focus Therapeutic Use
- 03 Oct 2017 Planned End Date changed from 30 Jan 2018 to 30 Mar 2018.
- 03 Oct 2017 Planned primary completion date changed from 15 Sep 2017 to 31 Jan 2018.
- 25 Aug 2017 Planned End Date changed from 1 Mar 2017 to 30 Jan 2018.